Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASZLDPF +0.96%49 EV-to-EBIT is 0.90 as of Jul. 23, 2026. GuruFocus rates ZLDPF with a GF Score™ of 49/100. The stock has 3 warning signs investors should review. Among 374 Biotechnology companies, Zealand Pharma AS ranks better than 77.01% on this metric.
Zealand Pharma AS (OTCPK:ZLDPF) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Zealand Pharma AS's Enterprise Value for the quarter that ended in Mar. 2026 was $985 Mil.
Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,076 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS EV-to-EBIT Related Terms
Zealand Pharma AS EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zealand Pharma AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's EV-to-EBIT falls into.
Zealand Pharma AS's current Enterprise Value is $965 Mil.
Zealand Pharma AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,076 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS (ZLDPF) has a EV-to-EBIT of 0.90 as of Jul. 23, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zealand Pharma AS and its competitors. According to the industry distribution chart, Zealand Pharma AS ranks #86 out of 374 companies in the Biotechnology industry, placing it in the top 23%.
Is Zealand Pharma AS's EV-to-EBIT too high?
Zealand Pharma AS's current EV-to-EBIT is 0.90. The Biotechnology industry median EV-to-EBIT is 13.04. Zealand Pharma AS's value of 0.90 is 93.1% below this industry median. Based on the distribution chart, Zealand Pharma AS ranks #86 out of 374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #86 out of 374 companies for EV-to-EBIT. This places Zealand Pharma AS in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 13.04. Zealand Pharma AS's value of 0.90 is 93.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.04, based on 374 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current EV-to-EBIT of 0.90 is 93.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current EV-to-EBIT is 0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (ZLDPF) has a current EV-to-EBIT of 0.90. The current EV-to-EBIT is 0.90 and 93.1% below the Biotechnology industry median of 13.04. Zealand Pharma AS's overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPF), the current EV-to-EBIT is 0.90 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
49GF Score
Get the complete analysis for ZLDPF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLDPF has been successfully added to your 
